Full Text View
Tabular View
No Study Results Posted
Related Studies
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
This study has been completed.
Study NCT00077545   Information provided by National Cancer Institute (NCI)

First Received on February 10, 2004.   Last Updated on December 21, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Adenocarcinoma of the Esophagus
Recurrent Esophageal Cancer
Stage IV Esophageal Cancer
Additional conditions recognized in this trial
Adenocarcinoma
Adenocarcinoma, Mucinous
Esophageal Diseases
Esophageal Neoplasms
More general conditions related to this trial
Carcinoma
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Head and Neck Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Cystic, Mucinous, and Serous
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
triapine
cisplatin
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services